Partnering is an integral component of our strategy which is to maximize the commercial potential of its pipeline and proprietary biociphering platforms thus expediting the development of new therapies for in the various autoimmune diseases we serve.

We view partnerships as a direct channel to near term, mid term and long term value creation and our goal is to collaborate with leading biotechnology and pharmaceutical companies by leveraging our robust platform technology as a complement for proteins and peptides that will result in enhanced therapies with substantial clinical and commercial potential.

Companies interested in exploring partnering opportunities with us should contact:

Partnering with ALLOZYNE